Bicycle Therapeutics (BCYC) Operating Expenses (2018 - 2026)

Bicycle Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $66.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 17.23% year-over-year to $66.4 million; the trailing twelve-month figure through Mar 2026 stood at $305.8 million (up 11.59% YoY), and the FY2025 full-year result was $319.7 million, up 30.39% from the prior year.
• Operating Expenses for Q1 2026 stood at $66.4 million, down from $72.7 million in the prior quarter.
• The five-year high for Operating Expenses was $89.5 million in Q2 2025, with the low at $31.2 million in Q1 2022.
• Historically, Operating Expenses has averaged $57.6 million across 5 years, with a median of $56.1 million in 2023.
• Annual changes were most pronounced in 2022 — Operating Expenses surged 76.08% — and 2026, when it slipped 17.23%.
• Bicycle Therapeutics' Operating Expenses stood at $35.4 million in 2022, then surged by 68.28% to $59.6 million in 2023, then advanced by 19.82% to $71.4 million in 2024, then gained by 1.81% to $72.7 million in 2025, then retreated by 8.66% to $66.4 million in 2026.
• The last three Operating Expenses figures came in at $66.4 million (Q1 2026), $72.7 million (Q4 2025), and $77.3 million (Q3 2025), per Business Quant data.